These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Keel RA; Tessier PR; Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2012 Aug; 56(8):4403-7. PubMed ID: 22687504 [TBL] [Abstract][Full Text] [Related]
7. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Douros A; Grabowski K; Stahlmann R Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865 [TBL] [Abstract][Full Text] [Related]
8. An evaluation of tedizolid for the treatment of MRSA infections. Hall RG; Smith WJ; Putnam WC; Pass SE Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779 [TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. Roger C; Roberts JA; Muller L Clin Pharmacokinet; 2018 May; 57(5):559-575. PubMed ID: 29063519 [TBL] [Abstract][Full Text] [Related]
10. Linezolid. Narang M; Gomber S Indian Pediatr; 2004 Nov; 41(11):1129-32. PubMed ID: 15591662 [TBL] [Abstract][Full Text] [Related]
12. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Ferrández O; Urbina O; Grau S Drug Des Devel Ther; 2017; 11():65-82. PubMed ID: 28053508 [TBL] [Abstract][Full Text] [Related]
13. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Choudhury S; Mun LK; Xuan ENC; Jia LS; Vasoo S; Wickramasinghe SS; Mee LJ J Clin Pathol; 2019 Feb; 72(2):181-184. PubMed ID: 30446512 [TBL] [Abstract][Full Text] [Related]
16. Oxazolidinones--a new class of broad-spectrum chemotherapeutics. Sztanke K; Pasternak K; Sztanke M Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):335-41. PubMed ID: 16146103 [TBL] [Abstract][Full Text] [Related]
17. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections. Delpech P; ALeryan M; Jones B; Gemmell C; Lang S Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of linezolid versus comparator therapies in Gram-positive infections. Wilcox MH J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140 [TBL] [Abstract][Full Text] [Related]
19. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Cattaneo D; Alffenaar JW; Neely M Expert Opin Drug Metab Toxicol; 2016 May; 12(5):533-44. PubMed ID: 26982718 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacological action and clinical effect of tedizolid phosphate (SIVEXTRO Mori M; Takase A Nihon Yakurigaku Zasshi; 2020; 155(5):332-339. PubMed ID: 32879176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]